Αποτελέσματα Αναζήτησης
14 Ιαν 2008 · The present data demonstrate that infants and young children require a considerably lower dose of clopidogrel per kilogram of body weight than do adults to achieve 30% to 50% inhibition of 5-μmol/L ADP–induced platelet aggregation, ie, the level of inhibition achieved with the approved adult dose.
- View Epub
PK ÛjXToa«, mimetypeapplication/epub+zipPK ÛjXT...
- Apoptosis Signal-Regulating Kinase 1/P38 Signaling Pathway Negatively Regulates Physiological Hypertrophy
Mitogen-activated protein kinase pathways play a key role in...
- View Epub
18 Αυγ 2004 · Because currently no recommended doses for clopidogrel in children are available, initial drug dosages may be extrapolated from adult regimens. Prospective pharmacokinetic and pharmacodynamic studies are needed to explore dosing, indications, and efficacy of clopidogrel in children.
The present study demonstrates that clopidogrel doses of 0.20 mg · kg 1 · d 1 in infants and young children 0 to 24 months of age with a systemic-to–pulmonary artery shunt or stent achieve platelet inhibition levels similar to those in adults taking the standard adult dose of clopidogrel 75 mg/d.
Clopidogrel dosages, duration of therapy, complications, and adverse effects in a pediatric population were explored. Results: Fifteen infants and children with congenital and acquired heart disease were treated with clopidogrel (median age, 3.5 years; range, 6 weeks to 16 years).
18 Αυγ 2004 · Fifteen infants and children with congenital and acquired heart disease were treated with clopidogrel (median age, 3.5 years; range, 6 weeks to 16 years). Dosages ranged from 1 to 6 mg/kg/day for periods between 1 month and 6 months.
Plavix is a medicine used to prevent problems caused by blood clots in adults who have: • recently had a myocardial infarction (heart attack). Plavix can be started between a few days and 35 days after the attack; • recently had an ischaemic stroke (stroke caused by failure of the blood supply to part of the brain).
1 Απρ 2019 · The results of the PICOLO trial showed that a dose of 0.2 mg/kg/day of clopidogrel in children aged 0–24 months achieved adequate inhibition of platelet function, comparable to that achieved in adults with a dose of 75 mg/day (approximately 1 mg/kg/day).
